Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM5167 in Advanced Solid Tumors
NCT07101601Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of lotixparib in solid tumor (advanced stage) (7 cohorts). Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Treatment Emergent Adverse Events and Serious Adverse Events. Started Oct 2024; status: recruiting.
02
Drugs
lotixparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07101601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101601.